On January 15, 2026, MetaVia Inc. entered into an Underwriting Agreement for a public offering, selling 614,840 Class A Units at $3.10 each and 1,998,704 Class B Units at approximately $3.099 each, raising around $7.7 million after expenses for developing DA-1726, a treatment for obesity. The offering closed on January 16, 2026.